Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer P, Tausch E, von Tresckow J, Giza A, Robrecht S, Schneider C, Fürstenau M, Langerbeins P, Al-Sawaf O, Pelzer BW, Fink AM, Fischer K, Wendtner CM, Eichhorst B, Kneba M, Stilgenbauer S, Hallek M. Cramer P, et al. Among authors: robrecht s. Blood. 2021 Nov 11;138(19):1805-1816. doi: 10.1182/blood.2020010484. Blood. 2021. PMID: 34086865 Free PMC article. Clinical Trial.
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S. Kovacs G, et al. Among authors: robrecht s. J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305. J Clin Oncol. 2016. PMID: 27573660
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S. Edelmann J, et al. Among authors: robrecht s. Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2. Leukemia. 2017. PMID: 27909343 Free PMC article. Clinical Trial. No abstract available.
Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A, Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M, Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR. Tiao G, et al. Among authors: robrecht s. Leukemia. 2017 Oct;31(10):2244-2247. doi: 10.1038/leu.2017.201. Epub 2017 Jun 27. Leukemia. 2017. PMID: 28652578 Free PMC article. No abstract available.
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G. Al-Sawaf O, et al. Among authors: robrecht s. Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12. Leukemia. 2017. PMID: 28745332 No abstract available.
Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A. Klymenko T, et al. Among authors: robrecht s. Leukemia. 2018 Feb;32(2):364-375. doi: 10.1038/leu.2017.255. Epub 2017 Aug 14. Leukemia. 2018. PMID: 28804121 Free PMC article.
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Fink AM, et al. Among authors: robrecht s. Lancet Haematol. 2017 Oct;4(10):e475-e486. doi: 10.1016/S2352-3026(17)30171-0. Epub 2017 Sep 12. Lancet Haematol. 2017. PMID: 28916311 Clinical Trial.
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D. Wolf C, et al. Among authors: robrecht s. Int J Cancer. 2018 Jan 15;142(2):322-333. doi: 10.1002/ijc.31057. Epub 2017 Oct 9. Int J Cancer. 2018. PMID: 28921505 Free article.
Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia.
Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR. Tiao G, et al. Among authors: robrecht s. Blood. 2017 Nov 30;130(22):2443-2444. doi: 10.1182/blood-2017-08-800128. Epub 2017 Oct 19. Blood. 2017. PMID: 29051179 Free PMC article. No abstract available.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Cramer P, et al. Among authors: robrecht s. Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13. Lancet Oncol. 2018. PMID: 30115596 Clinical Trial.
62 results